Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.
https://www.pharmalive.com/wp-content/uploads/2023/02/BioSpaceNovartis2-1-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-02-01 11:59:312023-02-01 11:59:31Huntington’s program bites the dust as Novartis cleans house